ES2179473T3 - Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local. - Google Patents

Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.

Info

Publication number
ES2179473T3
ES2179473T3 ES98911614T ES98911614T ES2179473T3 ES 2179473 T3 ES2179473 T3 ES 2179473T3 ES 98911614 T ES98911614 T ES 98911614T ES 98911614 T ES98911614 T ES 98911614T ES 2179473 T3 ES2179473 T3 ES 2179473T3
Authority
ES
Spain
Prior art keywords
capsaicin
site
anesthesia
pain
capsaicine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98911614T
Other languages
English (en)
Other versions
ES2179473T5 (es
Inventor
James N Campbell
Marco Pappagallo
Richard A Meyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2179473(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Publication of ES2179473T3 publication Critical patent/ES2179473T3/es
Application granted granted Critical
Publication of ES2179473T5 publication Critical patent/ES2179473T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención se refiere a procedimientos y composiciones destinada al tratamiento del dolor en una zona específica, con una concentración efectiva de capsaicina o de análogos de capsaicina. Los procedimientos consisten en anestesiar la zona donde la capsaicina o los derivados de capsaicina deben ser administrados, y en administrar una concentración efectiva de capsaicina en la articulación. Se puede anestesiar directamente la zona en cuestión o una zona a distancia de donde la anestesia puede alcanzar la zona de administración de la capsaicina. Por ejemplo, se puede efectuar una anestesia de la región epidural en los pacientes a quienes la capsaicina debe ser administrada en una zona situada en la parte inferior del cuerpo a partir de la dimensión. Al efectuar un tratamiento previo de la zona con un anestésico, se puede utilizar una concentración sensiblemente más elevada de capsaicina. Las concentraciones efectivas de capsaicina o de análogos de capsaicina están comprendidos entre 0,01 y 10% en peso, preferentemente entre 1 y 7,5% en peso, y son idealmente de aproximadamente un 5% en peso. Así, se puede aliviar mejor y de manera prolongada un dolo durante periodos que van de una a varias semanas. En ciertos casos, la suspensión del dolor puede ser más importante porque la afección que provoca el dolor puede conocer una mejora en razón de varios factores, en particular un mejor tratamiento físico gracias al reducción del dolor en los tejidos blandos, los que puede favorecer una mejor movilización de los tejidos blandos, tendones y articulaciones.
ES98911614T 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local. Expired - Lifetime ES2179473T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4069797P 1997-03-13 1997-03-13
US40697P 1997-03-13

Publications (2)

Publication Number Publication Date
ES2179473T3 true ES2179473T3 (es) 2003-01-16
ES2179473T5 ES2179473T5 (es) 2006-03-01

Family

ID=21912426

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98911614T Expired - Lifetime ES2179473T5 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
ES01204692T Expired - Lifetime ES2350755T3 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o análogos de capsaicina y un anestésico local.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES01204692T Expired - Lifetime ES2350755T3 (es) 1997-03-13 1998-03-12 Composiciones que contienen capsaicina o análogos de capsaicina y un anestésico local.

Country Status (11)

Country Link
US (1) US5962532A (es)
EP (2) EP0998288B2 (es)
JP (1) JP2001515492A (es)
AT (2) ATE219674T1 (es)
AU (1) AU720859B2 (es)
CA (1) CA2285203C (es)
DE (2) DE69806246T3 (es)
DK (2) DK1201241T3 (es)
ES (2) ES2179473T5 (es)
PT (2) PT1201241E (es)
WO (1) WO1998040070A1 (es)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6248788B1 (en) 1996-11-06 2001-06-19 The Regents Of The University Of California Therapeutic method with capsaicin and capasicin analogs
US6239180B1 (en) * 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
EP2198854B1 (en) 1997-09-18 2011-11-30 Pacira Pharmaceuticals, Inc. Sustained-release liposomal anesthetic compositions
EP1030652B1 (en) 1997-11-14 2012-04-25 Pacira Pharmaceuticals, Inc. Production of multivesicular liposomes
SE9800139D0 (sv) 1998-01-21 1998-01-21 Astra Ab New use
US6790207B2 (en) 1998-06-04 2004-09-14 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat disorders of the gastrointestinal tract
US6802841B2 (en) 1998-06-04 2004-10-12 Curon Medical, Inc. Systems and methods for applying a selected treatment agent into contact with tissue to treat sphincter dysfunction
AU752225B2 (en) 1998-07-17 2002-09-12 Pacira Pharmaceuticals, Inc. Biodegradable compositions for the controlled release of encapsulated substances
JP2004525071A (ja) * 2000-07-20 2004-08-19 ニューロジェン コーポレイション カプサイシン受容体リガンド
US20040146590A1 (en) 2001-03-22 2004-07-29 Iadarola Michael J Molecular neurochirurgie for pain control administering locally capsaicin or resinferatoxin
US20030096000A1 (en) * 2001-05-31 2003-05-22 Solis Rosa Maria Encapsulation of nanosuspensions in liposomes and microspheres
US20030105159A1 (en) * 2001-08-10 2003-06-05 Mccleary Joel Kavalactone compositions and methods of use
EP1450824A4 (en) * 2001-11-02 2005-09-28 Elan Corp Plc PHARMACEUTICAL COMPOSITION
CN1627944A (zh) * 2002-01-17 2005-06-15 神经能质公司 取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
DK1539124T3 (en) * 2002-09-05 2018-10-08 Vanderbilt Royalty Sub L P : COMPOSITIONS AND KITS FOR REMOVAL OF BODY SURFACES
CA2499994C (en) * 2002-09-23 2012-07-10 Verion, Inc. Abuse-resistant pharmaceutical compositions
US20040156931A1 (en) 2002-12-18 2004-08-12 Algorx Administration of capsaicinoids
PT1605956E (pt) * 2002-12-18 2016-03-09 Centrexion Therapeutics Corp Administração de capsaicinóides para o tratamento da osteoartrite
US7943166B2 (en) 2003-04-10 2011-05-17 Neurogesx, Inc. Methods and compositions for administration of TRPV1 agonists
JP5148271B2 (ja) * 2004-06-02 2013-02-20 ニューロジズエックス，インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
DE502004011941D1 (de) 2004-12-22 2011-01-05 Mestex Ag Mischung eines vanilloidrezeptoragonisten mit einer nervenregenerationshemmenden substanz, ihre verwendung für die herstellung eines schmerzmittels und verfahren zur applikation dieses mittels
EP1830835B1 (de) * 2004-12-28 2012-03-14 Mestex AG Verwendung eines vanilloidrezeptoragonisten zusammen mit einem glycosaminoglycan oder proteoglycan f]r die herstellung eines mittels zur behandlung von gelenkschmerzen und verfahren zur applikation dieses mittels
ES2533256T3 (es) 2004-12-28 2015-04-08 Mestex Ag Uso de resiniferatoxina (RTX) para la fabricación de un medicamento para el tratamiento del dolor
EP1858495A2 (en) * 2005-02-14 2007-11-28 Neurogesx, Inc. Device for delivery of trpv1 agonists
EP1865933B1 (en) * 2005-03-30 2015-11-04 Vanderbilt Royalty Sub L.P. Low-concentration capsaicin patch and methods for treating neuropathic pain
EP1865941B8 (en) * 2005-04-01 2010-12-22 Neurogesx, Inc. Oils of capsaicinoids and methods of making and using the same
US8916611B2 (en) * 2006-04-28 2014-12-23 Warsaw Orthopedic, Inc. Pharmaceutical removal of neuronal extensions from a degenerating disc
US7943666B2 (en) * 2006-07-24 2011-05-17 Trinity Laboratories, Inc. Esters of capsaicin for treating pain
US7645767B2 (en) * 2006-08-31 2010-01-12 Trinity Laboratories, Inc. Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
WO2009145842A2 (en) 2008-04-04 2009-12-03 Forsight Labs, Llc Therapeutic device for pain management and vision
US8158682B2 (en) * 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8987328B2 (en) * 2008-10-30 2015-03-24 Trinity Laboratories, Inc. Esters of capsaicinoids as dietary supplements
EP2427056A4 (en) * 2009-05-07 2012-08-22 Univ Cincinnati METHODS FOR PREVENTING ISCHEMIC LESION BY STIMULATION OF PERIPHERAL NICE PERIPHERAL
WO2011044381A1 (en) * 2009-10-07 2011-04-14 Inflasoothe, Inc. Pain relief composition, system and method
US9498385B2 (en) 2009-10-23 2016-11-22 Nexisvision, Inc. Conformable therapeutic shield for vision and pain
WO2011050327A1 (en) 2009-10-23 2011-04-28 Forsight Labs Llc Corneal denervation for treatment of ocular pain
US8591025B1 (en) 2012-09-11 2013-11-26 Nexisvision, Inc. Eye covering and refractive correction methods for LASIK and other applications
WO2012015882A1 (en) 2010-07-27 2012-02-02 Bean Bruce P Methods and compositions for preventing and relieving muscle cramps and for recovery from neuromuscular irritability and fatigue following exercise
JP2013544132A (ja) 2010-10-25 2013-12-12 ネクシスビジョン， インコーポレイテッド 視力のための眼被覆物を特定するための方法および装置
CN103328038A (zh) 2010-12-01 2013-09-25 史拜诺莫度雷森公司 向神经解剖结构直接递送药剂
US8678584B2 (en) 2012-04-20 2014-03-25 Nexisvision, Inc. Contact lenses for refractive correction
US12044905B2 (en) 2011-04-28 2024-07-23 Journey1 Inc Contact lenses for refractive correction
EP2701644B1 (en) 2011-04-28 2018-05-30 Nexisvision, Inc. Eye covering having improved tear flow, comfort, and/or applicability
EP3388057B1 (en) 2011-09-09 2022-03-09 Propella Therapeutics, Inc. A pain relief composition, comprising a trpv1 selective agonist, and manufacture and uses thereof
US9211274B2 (en) * 2012-02-01 2015-12-15 Warsaw Orthopedic, Inc. TRPV1 compounds in a biodegradable polymer carrier
US9465233B2 (en) 2012-04-20 2016-10-11 Nexisvision, Inc. Bimodular contact lenses
CA2871027A1 (en) 2012-04-20 2013-12-12 Nexisvision, Inc. Contact lenses for refractive correction
AU2013341380B2 (en) 2012-11-12 2018-04-26 Propella Therapeutics, Inc. Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid
CA2916885A1 (en) 2013-06-26 2014-12-31 Nexisvision, Inc. Contact lenses for refractive correction
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
US20150133561A1 (en) 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
US9341864B2 (en) 2013-11-15 2016-05-17 Nexisvision, Inc. Contact lenses having a reinforcing scaffold
WO2015116559A1 (en) 2014-01-29 2015-08-06 Nexisvision, Inc. Multifocal bimodulus contact lenses
MX377377B (es) 2014-04-15 2025-03-10 Propella Therapeutics Inc Composiciones tópicas para el alivio del dolor, manufactura y uso.
US11634384B2 (en) 2014-11-25 2023-04-25 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
EP3463576A4 (en) 2016-05-25 2020-01-15 Concentric Analgesics, Inc. PRODRUGS BY PHENOLIC TRPV1 AGONISTS IN COMBINATION WITH LOCAL ANESTHETIC AND VASOCONSTRICTORS FOR IMPROVED LOCAL ANESTHESIA
KR102657458B1 (ko) 2016-11-02 2024-04-12 센트렉시온 테라퓨틱스 코포레이션 안정한 수성의 캡사이신 주사 가능한 제형 및 이의 의학적 용도
WO2018136943A1 (en) 2017-01-23 2018-07-26 Flex Pharma, Inc. Compositions and methods affecting exercise performance
WO2019018769A1 (en) 2017-07-20 2019-01-24 Centrexion Therapeutics Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN USING CAPSAICINE
US20210283098A1 (en) * 2018-07-05 2021-09-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and Compositions for Treating Pain and Itch
US10717712B2 (en) 2018-07-27 2020-07-21 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic TRPV1 agonists
EP3840739B1 (en) 2018-08-24 2025-11-12 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
US11447444B1 (en) 2019-01-18 2022-09-20 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
US11254659B1 (en) 2019-01-18 2022-02-22 Centrexion Therapeutics Corporation Capsaicinoid prodrug compounds and their use in treating medical conditions
WO2022099284A1 (en) * 2020-11-05 2022-05-12 Young Biopharma, Llc Novel capsaicin analogs and uses thereof
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
GB2627096A (en) 2021-10-14 2024-08-14 Pacira Pharmaceuticals Inc Bupivacaine multivesicular liposome formulations and uses thereof
CN117883414B (zh) * 2024-03-18 2024-06-21 山东第二医科大学 一种长效缓释辣椒素微球及其制备方法和应用
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251468B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313958A (en) † 1980-10-24 1982-02-02 The Procter & Gamble Company Method of producing analgesia
US4424205A (en) * 1982-03-18 1984-01-03 The Procter & Gamble Company Hydroxyphenylacetamides having analgesic and anti-irritant activity
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4939149A (en) * 1988-10-24 1990-07-03 The United States Of America As Represented By The Department Of Health And Human Services Resiniferatoxin and analogues thereof to cause sensory afferent C-fiber and thermoregulatory desensitization
US5008289A (en) * 1988-12-02 1991-04-16 Galenpharma, Inc. Composition for treating nasal disorders and headaches
US4997853A (en) * 1988-12-02 1991-03-05 Galenpharma, Inc. Method and compositions utilizing capsaicin as an external analgesic
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5762963A (en) * 1995-06-07 1998-06-09 Emory University Method and compositions for controlling oral and pharyngeal pain using capsaicinoids

Also Published As

Publication number Publication date
ES2350755T3 (es) 2011-01-26
CA2285203C (en) 2005-07-26
JP2001515492A (ja) 2001-09-18
EP1201241B8 (en) 2010-10-27
ES2179473T5 (es) 2006-03-01
EP1201241A2 (en) 2002-05-02
EP0998288B2 (en) 2005-08-03
EP0998288B1 (en) 2002-06-26
AU720859B2 (en) 2000-06-15
DK0998288T3 (da) 2002-10-14
HK1027759A1 (en) 2001-01-23
DE69841907D1 (de) 2010-11-04
DE69806246T2 (de) 2003-02-06
CA2285203A1 (en) 1998-09-17
DK0998288T4 (da) 2005-08-22
AU6553298A (en) 1998-09-29
PT998288E (pt) 2002-11-29
ATE481970T1 (de) 2010-10-15
US5962532A (en) 1999-10-05
ATE219674T1 (de) 2002-07-15
WO1998040070A1 (en) 1998-09-17
DK1201241T3 (da) 2010-12-13
EP1201241A3 (en) 2004-01-02
EP1201241B1 (en) 2010-09-22
PT1201241E (pt) 2010-12-02
EP0998288A1 (en) 2000-05-10
DE69806246T3 (de) 2006-05-18
DE69806246D1 (de) 2002-08-01

Similar Documents

Publication Publication Date Title
ES2179473T3 (es) Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
DK1316308T3 (da) Transdermalt terapeutisk plaster med capsaicin og capsaicin-analoger
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
NL300382I1 (nl) Treatment of pompe's disease
DE69930758D1 (de) Verwendung von daptomycin
BR9812484A (pt) Terapia combinada para erradicação de hcv-rna detectável em pacientes com infecção crÈnica por hepatite c
NO305581B1 (no) Anvendelse av et benaktivt fosfonat i kombinasjon med et °strogenhormon, og preparat i enhetsdoseform for behandling av osteoporose
ATE181329T1 (de) Substituierte dibenzooxazepin-verbindungen, pharmazeutische zusammensetzungen und verfahren zur verwendung
ES2106531T3 (es) Compuestos de dibenzoxazepina substituidos en 2, 3, 4, 5, 6, 7, 8, 9 y/o 10, composiciones farmaceuticas y metodos de uso.
DE69420776D1 (de) Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer
KR890003390A (ko) 골다공증 및 관련된 장해의 치료방법
MX9300204A (es) Composicion farmaceutica que contiene azauridina para el tratamiento de la artritis reumatoide.
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE200617T1 (de) Pharmazeutische zusammensetzungen zur transdermalen verabreichung von melatonin und/oder seine analoge
DK0434989T3 (da) Fremgangsmåde til forbedring af ventilationen under søvn og til behandling af søvnrelaterede ventilationsabnormaliteter
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen